What is the elimination half‑life of Rexulti (brexpiprazole)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rexulti Half-Life

The elimination half-life of Rexulti (brexpiprazole) is 91 hours (approximately 3.8 days), with its major metabolite DM-3411 having a half-life of 86 hours 1.

Key Pharmacokinetic Details

Time to Steady State:

  • Brexpiprazole reaches steady-state concentrations within 10 to 12 days of once-daily dosing 1
  • This prolonged time to steady state is a direct consequence of the long elimination half-life

Peak Concentrations:

  • Peak plasma concentrations (Tmax) occur within 4 hours after oral administration 1
  • The median tmax in Japanese patients was 4-5 hours across all doses 2

Clinical Implications of the Long Half-Life

Dosing Considerations:

  • The 91-hour half-life means the drug accumulates 2.5- to 5.5-fold by day 14 compared to day 1 2
  • Steady-state levels are not achieved until after 10 days, so clinical effects may be delayed
  • Any dose adjustments should be made no more frequently than every 10-12 days to allow for equilibration

Drug Interactions:

  • Brexpiprazole is metabolized primarily by CYP3A4 and CYP2D6 1
  • Strong inhibitors of both enzymes can increase exposure up to 5.1-fold in extensive CYP2D6 metabolizers 1
  • The long half-life amplifies the clinical significance of drug interactions, as accumulation occurs over weeks

Discontinuation:

  • Due to the 91-hour half-life, brexpiprazole will remain in the system for approximately 2-3 weeks after the last dose (approximately 5 half-lives for complete elimination)
  • This extended washout period is relevant when switching to other antipsychotics or managing adverse effects

Metabolite Information

The major metabolite DM-3411 has a similar half-life of 86 hours and represents 23-48% of brexpiprazole exposure at steady state, though it does not contribute to therapeutic effects 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.